Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency department (ED) visits for adults […]
Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to […]
Cancer prevention and early detection measures show mixed progress, and substantial racial/ethnic, socioeconomic, and geographic disparities continue to exist according to the recent American Cancer Society […]
Forty-four percent of Canadian adults live with at least one chronic health condition such as heart disease, diabetes or a mood disorder. Up to 80 percent […]